Bacterial hybrid polyketide-nonribosomal peptide natural products reveal diverse structures and therapeutic potential from 2015-2025.
Background
Polyketide synthases (PKSs) and non-ribosomal peptide synthetases (NRPSs) are complex enzymatic machinery responsible for synthesizing a vast array of natural products, many of which are crucial antibiotics and therapeutics. While individual PKS or NRPS pathways are well-studied, hybrid PKS-NRPS systems integrate both biosynthetic logics, allowing for the incorporation of both acyl-CoA and amino acid-derived building blocks. These hybrid molecules often exhibit superior bioactivity and specificity against pathogens, tumors, or signaling pathways, making them highly attractive for drug discovery. Despite comprehensive reviews on fungal PKS-NRPS hybrids, a detailed summary of recent bacterial examples has been lacking, creating a knowledge gap this review addresses.
Study Design
This review systematically summarized bacterial hybrid PKS-NRPS natural products reported over the past decade, specifically from 2015-2025. The authors focused on elucidating their chemical structures, biological relevance, and underlying biosynthetic gene clusters. They also discussed potential biosynthetic pathways and the intricate domain arrangements within these fascinating systems. The scope included a comprehensive overview of the functional diversity observed across these bacterial hybrid molecules, aiming to provide a timely synthesis of recent advancements in the field.
Results
The review identified a significant and diverse array of bacterial hybrid PKS-NRPS natural products reported between 2015 and 2025, underscoring their widespread presence and importance. These compounds exhibit remarkable structural complexity, arising from the integrated biosynthetic logic of both PKS and NRPS pathways. Analysis of their biological relevance revealed potent activities, including antibacterial, antifungal, and anticancer properties, targeting various cellular processes and signaling pathways. The authors meticulously detailed numerous biosynthetic gene clusters, highlighting the genetic basis for the observed structural diversity and functional specialization. > A key finding was the elucidation of intricate domain arrangements and functional diversity within these hybrid systems, providing insights into the evolutionary ingenuity behind nature's chemical repertoire. Furthermore, the review discussed potential biosynthetic pathways, shedding light on the enzymatic mechanisms that govern the assembly of these complex molecules. This comprehensive overview emphasizes the untapped potential of bacterial PKS-NRPS hybrids as a rich source for novel therapeutic agents.
Key Findings
- Bacterial hybrid
PKS-NRPSnatural products exhibit significant structural diversity and biological relevance. - Detailed analysis of biosynthetic gene clusters reveals the genetic basis for complex molecular scaffolds.
- The review highlights potent antibacterial, antifungal, and anticancer activities of these compounds.
- Elucidation of domain arrangements provides insights into the evolutionary ingenuity of these systems.
- These hybrid systems represent a promising source for future therapeutic and biotechnological applications.
Why It Matters
This comprehensive review significantly advances our understanding of bacterial hybrid PKS-NRPS natural products, offering crucial insights for drug discovery and synthetic biology. For researchers and biohackers, the detailed overview of biosynthetic gene clusters and pathways provides a roadmap for engineering new-to-nature bioactive compounds with enhanced specificity and efficacy. The identified therapeutic potential, spanning antibiotics and anticancer agents, suggests that these systems are a fertile ground for developing novel clinical candidates. While not a direct protocol, this work informs the strategic design of future experiments, guiding efforts to manipulate these biosynthetic factories to produce tailored molecules. The insights into domain arrangements could lead to modular assembly strategies, accelerating the creation of next-generation therapeutics.